News
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations
Phase Four, a leading provider of next generation electric propulsion (EP) solutions for satellites, has been awarded a $14.9M contract by the Defense Advanced Research Projects Agency (DARPA) to deliver an "air-breathing" EP system to enable extended satellite operations in Very Low Earth Orbit (VLEO), at altitudes as low as
Read More
Achronix FPGAs add support for Bluespec’s Linux-capable RISC-V Soft Processors to enable scalable processing
Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Bluespec, Inc., an industry leader in RISC-V tools and silicon IP, has announced a family of Linux-capable RISC-V soft processors that are available for the Achronix Speedster®7t FPGA family. Marking an industry first, Bluespec’s RISC-V processors
Read More
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel
Read More
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, has announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD),
Read More
Resolve Therapeutics announces publication of Lupus clinical trial results
Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus
Read More
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet
Read More
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
The European Investment Bank (EIB) and Novadip have signed a €18 million venture debt financing agreement supported by the European Union’s InvestEU initiative. The Belgian biotech company will use the funds to support clinical trials of NVD-003, an autologous bone product that provides one-time curative treatment to achieve long-term union
Read More
Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring
Repeated Signal Solutions, Inc. (RSS) and Avari Wireless Inc. have announced the launch of Enhanced ERCES Monitoring™. Enhanced ERCES Monitoring™ is a new service that allows building owners to monitor their First Responder (ERCES) radio systems remotely with the same level of visibility as required by the NFPA code. "Enhanced
Read MoreNovadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in
Read MoreAvari Wireless awarded contract to provide radio communications coverage for the Toronto underground subway system pilot project
Avari Wireless has announced they are the winner of the tender to supply Distributed Antenna System (DAS) for the Toronto Transit Commission (TTC). The project’s scope is to supply engineering, equipment, materials, and other services to construct a Distributed Antenna System (DAS) using digital technologies, to provide radio communications coverage
Read MoreNorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting
NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver
Read More
Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs
Zeotap Data, a leading provider of fully-consented, people-based data solutions, is proud to introduce Validated Demos the key to delivering reach and frequency metrics against your core demographic audience in programmatic media buying. Through exclusive partnerships with Europe’s major mobile telco operators, Zeotap Data employs cutting-edge modelling techniques to leverage
Read More